DATATRAK Announces Next Release of eClinical Product Suite


Company News Release

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, has announced the newest release of its DATATRAK eClinical(TM) product suite.

DATATRAK Announces Next Release of eClinical Product Suite

Company continues to leverage efficiencies of its unified platform, expanding the richness, ease and detailed nature of clinical trial information through site performance metrics and standard reporting capabilities
    CLEVELAND, Oct. 1 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the newest release of its DATATRAK eClinical(TM) product suite.  This release of the Company's unified platform for global clinical trials, having successfully passed internal testing and validation requirements was placed into production on Saturday, September 27, 2008.        
    Several significant incremental advancements are represented by this version of DATATRAK eClinical.  First and foremost is the ease with which extensively detailed information about clinical trials can be obtained with this product suite.  An example of the information that is automatically tracked by this platform includes metrics on investigative site performance.  Such information is critical to clinical trial sponsors when deciding where to place specific clinical studies as efficient enrollment of patients is often the reason why clinical trial timeframes are delayed and projections are missed, resulting in an increased overall cost for research and development.  With this version of DATATRAK eClinical, as long as this platform is consistently used, clinical trial sponsors will be able to characterize the historic quality of a research site before the clinical trial is started, potentially avoiding a key delay factor in drug and device development worldwide.   
    This version of DATATRAK eClinical now contains capabilities for Japanese/Kanji-character translation, making this platform more readily accepted in the third largest clinical trial market in the world.  The clinical trials recently won by NTT DATA in Japan will initiate enrollment during the Fourth Quarter of 2008 with this new release.   
    A complete listing of the new and enhanced functionalities of the eClinical product suite can be found by going to the following link: .
    "Our unified architectural platform continues to allow for efficient and rapid development and expansion of our product suite capabilities, probably more than any other software in this industry," stated Dr. Jeffrey A. Green, Chief Executive Officer of DATATRAK International, Inc.  "Importantly, we can accomplish all of this without having to integrate with unrelated applications, thereby saving our customers time and money from alternative approaches.  We believe the capability to quantify in an effortless manner quantitative statistics on site metrics and performance in clinical trials will be increasingly viewed as important by our customers and represents a future differentiating capability within this market." 

    About DATATRAK International, Inc.
    DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry.   The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the United States Food and Drug Administration (FDA), faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients.  The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the FDA or counterpart European bodies.  DATATRAK International, Inc. has offices located in Cleveland, Ohio and Bryan, Texas.  Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA".  Visit the DATATRAK International, Inc. web site at .
    Except for the historical information contained in this press release, the statements made in this release are forward-looking statements.  These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights; delisting of the Company's common shares from the Nasdaq due to our failure to continue to meet applicable Nasdaq Capital Market requirements; the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; the outcome of the Company's disputes with former shareholders of ClickFind, Inc.; the effects and outcomes of the Company's exploration of potential opportunities directed at maximizing shareholder value; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets.  This list of factors is not all inclusive.  In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.
SOURCE  DATATRAK International, Inc.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.